SpyGlass Pharma Inc Dossier
Qualitative Analysis
Business overview
SpyGlass Pharma Inc (Nasdaq: SGP) is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Founded in 2019 and based in Aliso Viejo, California, the company's proprietary platform technology integrates known drugs, procedures, and devices to provide long-term disease control and vision preservation. Its lead product candidate is the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which consists of non-bioerodible drug pads attached to a monofocal intraocular lens (IOL) implanted during routine cataract surgery to deliver glaucoma treatment and lower intraocular pressure (IOP) for up to three years. Additionally, SpyGlass is developing the Bimatoprost Drug Ring System (BIM-DRS), a non-IOL-based, ring-shaped, sustained-release implant designed for glaucoma patients who are not undergoing cataract surgery.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), through two registrational Phase 3 clinical trials (SGP-005 and SGP-006) to demonstrate non-inferiority in lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Expected impact: Establish a new procedure-based standard of care that seamlessly integrates multi-year sustained drug delivery into routine cataract surgery, eliminating daily eye drops for patients.
Developing the Bimatoprost Drug Ring System (BIM-DRS), a removable and replaceable, non-IOL-based, ring-shaped implant designed to provide multi-year drug delivery and enable retreatment.
Expected impact: Expands the company's addressable market to include pseudophakic glaucoma patients and those not undergoing cataract surgery, targeting a standalone glaucoma market valued at $6 billion to $7 billion.
Conducting preclinical studies to evaluate the delivery of other therapeutic agents using the SpyGlass polymer pad platform, including small molecules for age-related macular degeneration (AMD), as well as corticosteroids and NSAIDs for postoperative inflammation.
Expected impact: Leverage the modular design and programmable drug release of the core platform to address both anterior and posterior segment chronic eye diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
SpyGlass Pharma holds an exclusive license with the Regents of the University of Colorado. The core SpyGlass drug delivery platform was originally developed at the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and spun off in 2019. CU Innovations continues to collaborate on patent and IP portfolio expansion.
Terms: Specific financial terms of the exclusive licensing agreement are confidential, but the partnership includes ongoing collaboration on IP protection.